JoVE Visualize What is visualize?
Stop Reading. Start Watching.
Advanced Search
Stop Reading. Start Watching.
Regular Search
Find video protocols related to scientific articles indexed in Pubmed.
Viral load versus CD4? monitoring and 5-year outcomes of antiretroviral therapy in HIV-positive children in Southern Africa: a cohort-based modelling study.
AIDS
PUBLISHED: 11-14-2014
Show Abstract
Hide Abstract
Many paediatric antiretroviral therapy (ART) programmes in Southern Africa rely on CD4? to monitor ART. We assessed the benefit of replacing CD4? by viral load monitoring.
Related JoVE Video
Pharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir/ritonavir.
J. Antimicrob. Chemother.
PUBLISHED: 10-05-2014
Show Abstract
Hide Abstract
Co-treatment of HIV and TB in young children is complicated by limited treatment options and complex drug-drug interactions. Rifabutin is an alternative to rifampicin for adults receiving a ritonavir-boosted PI. We aimed to evaluate the short-term safety and pharmacokinetics of rifabutin when given with lopinavir/ritonavir in children.
Related JoVE Video
Predictors of virologic and clinical response to nevirapine versus lopinavir/ritonavir-based antiretroviral therapy in young children with and without prior nevirapine exposure for the prevention of mother-to-child HIV transmission.
Pediatr. Infect. Dis. J.
PUBLISHED: 09-16-2014
Show Abstract
Hide Abstract
In a randomized trial comparing nevirapine (NVP)-based versus lopinavir/ritonavir (LPV/r)-based antiretroviral therapy (ART) in HIV-infected children [primary endpoint discontinuation of study treatment for any reason or virologic failure by week 24] aged 2 months to 3 years, we assessed whether clinical, virologic, immunologic and safety outcomes varied by prior single-dose NVP exposure (PrNVP) for prevention of mother-to-child HIV transmission and other covariates.
Related JoVE Video
The effect of tuberculosis treatment on virologic and immunologic response to combination antiretroviral therapy among South African children.
J. Acquir. Immune Defic. Syndr.
PUBLISHED: 07-30-2014
Show Abstract
Hide Abstract
Many HIV-infected children are diagnosed with tuberculosis (TB), but the effect of TB treatment on virologic and immunologic response to combination antiretroviral therapy (cART) is not well documented.
Related JoVE Video
Tuberculosis Immune Reconstitution Inflammatory Syndrome in Children Initiating Antiretroviral Therapy for HIV Infection: A Systematic Literature Review.
Pediatr. Infect. Dis. J.
PUBLISHED: 04-17-2014
Show Abstract
Hide Abstract
People with HIV initiating combination antiretroviral therapy are at risk for tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS). While this syndrome has been well researched in adults, little is known about the incidence, case fatality, underlying immunopathology and treatment approaches in children.
Related JoVE Video
Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype.
AIDS
PUBLISHED: 11-02-2013
Show Abstract
Hide Abstract
An efavirenz-based antiretroviral therapy (ART) regimen is preferred for children more than 3 years of age with tuberculosis. However, rifampin, a key component of antituberculosis therapy, induces CYP2B6. An increased dose of efavirenz is recommended in adults weighing more than 50 kg who require rifampin, but there is scant information in children being treated for tuberculosis.
Related JoVE Video
When to start antiretroviral therapy in children aged 2-5 years: a collaborative causal modelling analysis of cohort studies from southern Africa.
PLoS Med.
PUBLISHED: 11-01-2013
Show Abstract
Hide Abstract
There is limited evidence on the optimal timing of antiretroviral therapy (ART) initiation in children 2-5 y of age. We conducted a causal modelling analysis using the International Epidemiologic Databases to Evaluate AIDS-Southern Africa (IeDEA-SA) collaborative dataset to determine the difference in mortality when starting ART in children aged 2-5 y immediately (irrespective of CD4 criteria), as recommended in the World Health Organization (WHO) 2013 guidelines, compared to deferring to lower CD4 thresholds, for example, the WHO 2010 recommended threshold of CD4 count <750 cells/mm(3) or CD4 percentage (CD4%) <25%.
Related JoVE Video
Frequency of stavudine substitution due to toxicity in children receiving antiretroviral treatment in sub-Saharan Africa.
AIDS
PUBLISHED: 10-30-2013
Show Abstract
Hide Abstract
Stavudine is a commonly used drug in paediatric antiretroviral treatment (ART) regimens. Due to toxicity concerns, however, the drug abacavir has replaced stavudine in first-line paediatric regimens in many countries. We describe the frequency of stavudine toxicity in children receiving ART at a treatment clinic in Soweto, South Africa.
Related JoVE Video
Cost and outcomes of paediatric antiretroviral treatment in South Africa.
AIDS
PUBLISHED: 06-14-2013
Show Abstract
Hide Abstract
Little is known about the cost of paediatric antiretroviral treatment (ART) in low-income and middle-income countries. We analysed the average cost of providing paediatric ART in South Africa during the first 2 years after ART initiation, stratified by patient outcomes.
Related JoVE Video
Predictors of loss to follow-up among children in the first and second years of antiretroviral treatment in Johannesburg, South Africa.
Glob Health Action
PUBLISHED: 02-01-2013
Show Abstract
Hide Abstract
Ninety percent of the worlds 2.1 million HIV-infected children live in sub-Saharan Africa, and 2.5% of South African children live with HIV. As HIV care and treatment programmes are scaled-up, a rise in loss to follow-up (LTFU) has been observed.
Related JoVE Video
Temporal Trends in the Characteristics of Children at Antiretroviral Therapy Initiation in Southern Africa: The IeDEA-SA Collaboration.
PLoS ONE
PUBLISHED: 01-01-2013
Show Abstract
Hide Abstract
Since 2005, increasing numbers of children have started antiretroviral therapy (ART) in sub-Saharan Africa and, in recent years, WHO and country treatment guidelines have recommended ART initiation for all infants and very young children, and at higher CD4 thresholds for older children. We examined temporal changes in patient and regimen characteristics at ART start using data from 12 cohorts in 4 countries participating in the IeDEA-SA collaboration.
Related JoVE Video
Accuracy of immunological criteria for identifying virological failure in children on antiretroviral therapy - the IeDEA Southern Africa Collaboration.
Trop. Med. Int. Health
PUBLISHED: 08-11-2011
Show Abstract
Hide Abstract
To determine the diagnostic accuracy of World Health Organization (WHO) 2010 and 2006 as well as United States Department of Health and Human Services (DHHS) 2008 definitions of immunological failure for identifying virological failure (VF) in children on antiretroviral therapy (ART).
Related JoVE Video
Antiretroviral therapy responses among children attending a large public clinic in Soweto, South Africa.
Pediatr. Infect. Dis. J.
PUBLISHED: 07-08-2011
Show Abstract
Hide Abstract
Antiretroviral therapy (ART) access with successful outcomes for children is expanding in resource-limited countries. The aim of this study was to determine treatment responses of children in a routine setting where first-line therapy with lopinavir/ritonavir is routinely included for young children.
Related JoVE Video
Virologic failure and second-line antiretroviral therapy in children in South Africa--the IeDEA Southern Africa collaboration.
J. Acquir. Immune Defic. Syndr.
PUBLISHED: 04-05-2011
Show Abstract
Hide Abstract
With expanding pediatric antiretroviral therapy (ART) access, children will begin to experience treatment failure and require second-line therapy. We evaluated the probability and determinants of virologic failure and switching in children in South Africa.
Related JoVE Video
Antiretroviral therapy outcomes in HIV-infected children after adjusting protease inhibitor dosing during tuberculosis treatment.
PLoS ONE
PUBLISHED: 01-26-2011
Show Abstract
Hide Abstract
Modification of ritonavir-boosted lopinavir (LPV/r)-based antiretroviral therapy is required for HIV-infected children co-treated for tuberculosis (TB). We aimed to determine virologic and toxicity outcomes among TB/HIV co-treated children with the following modifications to their antiretroviral therapy (ART): (1) super-boosted LPV/r, (2) double-dose LPV/r or (3) ritonavir.
Related JoVE Video
Early mortality and loss to follow-up in HIV-infected children starting antiretroviral therapy in Southern Africa.
J. Acquir. Immune Defic. Syndr.
PUBLISHED: 07-01-2010
Show Abstract
Hide Abstract
Many HIV-infected children in Southern Africa have been started on antiretroviral therapy (ART), but loss to follow up (LTFU) can be substantial. We analyzed mortality in children retained in care and in all children starting ART, taking LTFU into account.
Related JoVE Video
Effect on mortality and virological response of delaying antiretroviral therapy initiation in children receiving tuberculosis treatment.
AIDS
PUBLISHED: 06-19-2010
Show Abstract
Hide Abstract
To estimate the effect of delaying antiretroviral treatment (ART) for 15, 30, or 60 days after tuberculosis (TB) treatment initiation on mortality and virological suppression.
Related JoVE Video
Monitoring the South African National Antiretroviral Treatment Programme, 2003-2007: the IeDEA Southern Africa collaboration.
S. Afr. Med. J.
PUBLISHED: 04-02-2009
Show Abstract
Hide Abstract
To introduce the combined South African cohorts of the International epidemiologic Databases to Evaluate AIDS Southern Africa (IeDEA-SA) collaboration as reflecting the South African national antiretroviral treatment (ART) programme; to characterise patients accessing these services; and to describe changes in services and patients from 2003 to 2007.
Related JoVE Video
Outcomes of the South African National Antiretroviral Treatment Programme for children: the IeDEA Southern Africa collaboration.
S. Afr. Med. J.
PUBLISHED: 02-25-2009
Show Abstract
Hide Abstract
To assess paediatric antiretroviral treatment (ART) outcomes and their associations from a collaborative cohort representing 20% of the South African national treatment programme.
Related JoVE Video
Variability of growth in children starting antiretroviral treatment in southern Africa.
Pediatrics
Show Abstract
Hide Abstract
Poor growth is an indication for antiretroviral therapy (ART) and a criterion for treatment failure. We examined variability in growth response to ART in 12 programs in Malawi, Zambia, Zimbabwe, Mozambique, and South Africa.
Related JoVE Video
The role of targeted viral load testing in diagnosing virological failure in children on antiretroviral therapy with immunological failure.
Trop. Med. Int. Health
Show Abstract
Hide Abstract
To determine the improvement in positive predictive value of immunological failure criteria for identifying virological failure in HIV-infected children on antiretroviral therapy (ART) when a single targeted viral load measurement is performed in children identified as having immunological failure.
Related JoVE Video
Effect of baseline immune suppression on growth recovery in HIV positive South African children receiving antiretroviral treatment.
J. Acquir. Immune Defic. Syndr.
Show Abstract
Hide Abstract
Growth failure is common among children infected with HIV. The degree of growth recovery and its determinants in children initiating combination antiretroviral therapy (cART) are not well understood.
Related JoVE Video
Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children.
N. Engl. J. Med.
Show Abstract
Hide Abstract
Nevirapine-based antiretroviral therapy is the predominant (and often the only) regimen available for children in resource-limited settings. Nevirapine resistance after exposure to the drug for prevention of maternal-to-child human immunodeficiency virus (HIV) transmission is common, a problem that has led to the recommendation of ritonavir-boosted lopinavir in such settings. Regardless of whether there has been prior exposure to nevirapine, the performance of nevirapine versus ritonavir-boosted lopinavir in young children has not been rigorously established.
Related JoVE Video
Virologic Response in Children Treated with Abacavir Compared with Stavudine-Based Antiretroviral Treatment - A South African Multi-Cohort Analysis.
Pediatr. Infect. Dis. J.
Show Abstract
Hide Abstract
Initiation criteria and pediatric antiretroviral treatment (ART) regimens have changed over the past few years in South Africa. We reported worse early virological outcomes associated with the use abacavir (ABC)-based regimens at one large site: here we expand this analysis to multiple sites in the IeDEA-Southern Africa collaboration.
Related JoVE Video
Prognosis of Children with HIV-1 Infection Starting Antiretroviral Therapy in Southern Africa: A Collaborative Analysis of Treatment Programs.
Pediatr. Infect. Dis. J.
Show Abstract
Hide Abstract
Prognostic models for children starting antiretroviral therapy (ART) in Africa are lacking. We developed models to estimate the probability of death during the first year receiving ART in Southern Africa.
Related JoVE Video

What is Visualize?

JoVE Visualize is a tool created to match the last 5 years of PubMed publications to methods in JoVE's video library.

How does it work?

We use abstracts found on PubMed and match them to JoVE videos to create a list of 10 to 30 related methods videos.

Video X seems to be unrelated to Abstract Y...

In developing our video relationships, we compare around 5 million PubMed articles to our library of over 4,500 methods videos. In some cases the language used in the PubMed abstracts makes matching that content to a JoVE video difficult. In other cases, there happens not to be any content in our video library that is relevant to the topic of a given abstract. In these cases, our algorithms are trying their best to display videos with relevant content, which can sometimes result in matched videos with only a slight relation.